NCT07526961 2026-04-14
Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland
Bristol-Myers Squibb
Completed
Bristol-Myers Squibb
Novartis
Novartis
University of Chicago
Akeso
Abramson Cancer Center at Penn Medicine
National Cancer Institute (NCI)
Fundación GECP
Syndax Pharmaceuticals